First ‘Digital Medicine’ Approved, Slow Rollout Planned
FDA has approved Abilify MyCite, a treatment for some psychiatric conditions that integrates a drug with a sensor that records when the medication is taken. The goal is to track medication compliance. It is an important regulatory milestone for the nascent field of digital medicine, but many questions about the market remain.
You may also be interested in...
Bringing A Digital Pill To Oncology: Proteus Partners With Health System To Prescribe Sensor-Enabled Chemotherapy
Proteus Digital Health announced a new partnership with Fairview Health Services and the University of Minnesota Health to prescribe capecitabine, a common chemotherapy drug, encapsulated with a sensor to colorectal cancer patients. Under the program, patients are prescribed the "digital capecitabine" and will be monitored remotely to see when they take their meds and for other health data. The goal is to improve patients' treatment adherence and improve outcomes.
Strategic Fingers In Digital Health Pies
Investors in digital health are a different breed. They invest less than life science investors, and they expect (and receive) more rapid returns. What's more, the corporate, strategic investment funds are not simply the venture arms of big pharma and medtech; health insurers and the tech firms are in there, too. And, guess what – they have entirely different agendas.
2018 An Inflection Point For mHealth After An Active Year
The past year saw US FDA and industry work hard and fast to prepare for what looks like an inevitable boom in the digital-health sector. According to interviews, the time is ripe for adoption of mobile health apps to help reduce health-care costs, but the brave new world also brings with it big challenges.